Insights Into Diffuse Large B-Cell Lymphoma (DLBCL)
Perspectives on drivers in treatment decisions in the management of DLBCL, perception of various therapeutics, and understanding of the current and future treatment landscape
Florida – February 9, 2024
Faculty Chair
Nikesh Shah, MD
Tampa General Hospital, Tampa, FL, USA
Southwest – February 24, 2024
Faculty Chair
John Burke, MD
Rocky Mountain Cancer Centers, Aurora, CO, USA
Southeast – March 15, 2024
Faculty Chair
Amitkumar Mehta, MD
University of Alabama, Birmingham, AL, USA
Central – April 20, 2024
Faculty Chair
Mazyar Shadman, MD
Fred Hutchinson Cancer Center, Seattle, WA, USA
More Information
- Tampa, FL
- Florida
More Information
- Scottsdale, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Atlanta, GA
- Alabama, Florida, Georgia, Kentucky, Mississippi, North Carolina, South Carolina, Tennessee, Virginia, West Virginia
More Information
- Dallas, TX
- Arkansas, Kansas, Louisiana, Missouri, Oklahoma, Texas
More Information
- Philadelphia, PA
- Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
MORE INFORMATION
- San Diego, CA
- California
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of DLBCL
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: rituximab, lenalidomide, obinutuzumab, idelalisib, bortezomib, ibrutinib, axicabtagene ciloleucel, and polatuzumab vedotin
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
